Peringatan Keamanan

As elapegademase is a therapeutic protein, there is a potential risk of immunogenicity.

There are no studies related to overdose but the highest weekly prescribed dose in clinical trials was 0.4 mg/kg. In nonclinical studies, a dosage of 1.8 fold of the clinical dose produced a slight increase in the activated partial thromboplastin time.^{FDA label}

Elapegademase

DB14712

biotech approved

Deskripsi

Elapegademase is a PEGylated recombinant adenosine deaminase. It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues.^F1937 Elapegademase is generated in E. coli, developed by Leadiant Biosciences and FDA approved on October 5, 2018.L4654,F1939

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) This pharmacokinetic property has not been fully studied.

Volume Distribusi This pharmacokinetic property has not been fully studied.

Klirens (Clearance) This pharmacokinetic property has not been fully studied.

Absorpsi

Elapegademase is administered intramuscularly and the reported Tmax, Cmax and AUC are approximately 60 hours, 240 mmol.h/L and 33000 hr.mmol/L as reported during a week.^{FDA label}

Metabolisme

Metabolism studies have not been performed but it is thought to be degraded by proteases to small peptides and individual amino acids.

Rute Eliminasi

This pharmacokinetic property has not been fully studied.

Interaksi Obat

36 Data

Peginterferon alfa-2a	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfa-2b.
Pegaspargase	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegaspargase.
Pegademase	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegademase.
Pegvisomant	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvisomant.
Propylene glycol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Propylene glycol.
Heptaethylene glycol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Heptaethylene glycol.
Pegaptanib	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegaptanib.
Egaptivon pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Egaptivon pegol.
PEG-uricase	The therapeutic efficacy of Elapegademase can be decreased when used in combination with PEG-uricase.
Peginterferon alfacon-1	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfacon-1.
GlycoPEG-GCSF	The therapeutic efficacy of Elapegademase can be decreased when used in combination with GlycoPEG-GCSF.
Pegnivacogin	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegnivacogin.
Pegpleranib	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegpleranib.
Pegsunercept	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegsunercept.
Polidocanol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polidocanol.
Peginesatide	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginesatide.
Certolizumab pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Certolizumab pegol.
Methoxy polyethylene glycol-epoetin beta	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.
Peginterferon beta-1a	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon beta-1a.
Pegloticase	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegloticase.
Polyethylene glycol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polyethylene glycol.
Antihemophilic factor (recombinant), PEGylated	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Antihemophilic factor (recombinant), PEGylated.
Insulin peglispro	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Insulin peglispro.
Eptacog alfa pegol (activated)	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Eptacog alfa pegol (activated).
Olaptesed Pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Olaptesed Pegol.
Abicipar Pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Abicipar Pegol.
Lexaptepid pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Lexaptepid pegol.
Cepeginterferon alfa-2B	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Cepeginterferon alfa-2B.
Pegvaliase	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvaliase.
Pegamotecan	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegamotecan.
Lipegfilgrastim	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Lipegfilgrastim.
Nonacog beta pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Nonacog beta pegol.
Damoctocog alfa pegol	The therapeutic efficacy of Elapegademase can be decreased when used in combination with Damoctocog alfa pegol.
Rurioctocog alfa pegol	The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Elapegademase.

Target Protein

Adenosine

Referensi & Sumber

Link

Attachment

Contoh Produk & Brand

Produk: 2 • International brands: 0

Produk

Revcovi

Injection • 1.6 mg/1mL • Intramuscular • US • Approved
Revcovi

Injection • 1.6 mg/1mL • Intramuscular • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.